A comparative study on micelles, liposomes and solid lipid nanoparticles for paclitaxel delivery.
LDV
Liposomes
Micelles
Paclitaxel
Solid Lipid Nanoparticles
Targeting
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Jan 2023
25 Jan 2023
Historique:
received:
18
08
2022
revised:
13
11
2022
accepted:
27
11
2022
pubmed:
5
12
2022
medline:
14
1
2023
entrez:
4
12
2022
Statut:
ppublish
Résumé
The purpose of this work was to compare the in vitro and in vivo characteristics of LDV-targeted lipid-based micelles, liposomes and solid lipid nanoparticles (SLN) to provide further insights into their therapeutic potential for clinical development. Micelles, liposomes and SLN were prepared using LDV peptide amphiphiles and palmitic acid-derived lipids using solvent evaporation, thin-film hydration and microfluidic mixing respectively. Nanocarriers were characterized for their physicochemical properties, paclitaxel loading efficiency, in vitro release behavior, stability in biological media as well as in vivo antitumor efficacy in melanoma xenograft model. TEM and DLS results confirmed the presence of paclitaxel-loaded nanosized micelles (6 to 12 nm), liposomes (123.31 ± 5.87 nm) and SLN (80.53 ± 5.37 nm). SLN demonstrated the slowest paclitaxel release rate and the highest stability in biological media compared to micelles and liposomes. Paclitaxel-loaded SLN demonstrated a statistically significant delay in tumor growth compared to mice treated with paclitaxel-loaded liposomes and paclitaxel-loaded micelles (p < 0.05). The results obtained in this study indicate the potential of SLN as drug delivery vehicles for anticancer therapy.
Identifiants
pubmed: 36464111
pii: S0378-5173(22)01019-5
doi: 10.1016/j.ijpharm.2022.122464
pii:
doi:
Substances chimiques
Lipid Nanoparticles
0
Liposomes
0
Paclitaxel
P88XT4IS4D
Micelles
0
Drug Carriers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122464Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.